Halozyme Therapeutics (HALO) News Today $45.56 -0.20 (-0.44%) (As of 10:25 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Aurora Investment Counsel Sells 12,753 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Aurora Investment Counsel reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,350 shares of the biopharmaceuticaNovember 21 at 6:51 AM | marketbeat.comSegall Bryant & Hamill LLC Has $20.33 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Segall Bryant & Hamill LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 355,176 sharesNovember 21 at 5:02 AM | marketbeat.comHalozyme’s Competitive Edge: Butler’s Buy Rating Amid Emerging CompetitorsNovember 21 at 12:18 AM | markets.businessinsider.comHalozyme’s Transformative Acquisition of Evotec: A Strategic Move for Growth and Market ExpansionNovember 21 at 12:18 AM | markets.businessinsider.comHalozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec DealNovember 19 at 11:11 PM | seekingalpha.comHalozyme Therapeutics (NASDAQ:HALO) Shares Gap Up - Here's WhyHalozyme Therapeutics (NASDAQ:HALO) Shares Gap Up - Here's What HappenedNovember 19 at 1:34 PM | marketbeat.comEvotec plunges amid report it's against Halozyme Therapeutics takeoverNovember 19 at 11:23 AM | msn.comVictory Capital Management Inc. Has $23.29 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Victory Capital Management Inc. lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 96.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 406,811 shares of the biopharmaceutical coNovember 19 at 3:49 AM | marketbeat.comHalozyme says €2 billion takeover of Evotech would create leader in drug discoveryNovember 18 at 8:01 AM | marketwatch.comHalozyme Provides Update on Non-Binding Proposal to Combine with EvotecNovember 18 at 7:00 AM | prnewswire.comRoyce & Associates LP Has $7.10 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Royce & Associates LP trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 29.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 124,011 shares of the biopharmaceuticaNovember 18 at 4:42 AM | marketbeat.comHalozyme plans finance $2.1 takeover of Evotech in cash: reportNovember 17, 2024 | msn.comHalozyme to Fund Proposed Evotec Takeover in Cash, CEO SaysNovember 17, 2024 | bloomberg.comCornercap Investment Counsel Inc. Sells 20,204 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Cornercap Investment Counsel Inc. reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 71.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,007 shares of the biopharmaceutical coNovember 17, 2024 | marketbeat.comSouth Street Advisors LLC Purchases New Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)South Street Advisors LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 171,415 shares of the biopharmaceutical company'sNovember 16, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Mizuho Markets Americas LLCMizuho Markets Americas LLC lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 375,446 shares of the biopharmaceutical company's stockNovember 16, 2024 | marketbeat.comPiper Sandler Sticks to Its Hold Rating for Halozyme (HALO)November 16, 2024 | markets.businessinsider.comLarge Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 BillionNovember 15, 2024 | finance.yahoo.comHalozyme Therapeutics sinks after confirming $2B Evotec buyout offerNovember 15, 2024 | seekingalpha.comHalozyme Therapeutics (NASDAQ:HALO) Shares Gap Down - Here's What HappenedHalozyme Therapeutics (NASDAQ:HALO) Shares Gap Down - Here's WhyNovember 15, 2024 | marketbeat.comHalozyme’s Strategic Acquisition of Evotec: A Buy Rating for Future Growth and ProfitabilityNovember 15, 2024 | markets.businessinsider.comHalozyme makes 2 billion euro buyout offer for drug developer EvotecNovember 14, 2024 | msn.comHalozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash TransactionNovember 14, 2024 | prnewswire.comHalozyme weighing buyout of drugmaker Evotec, Bloomberg News reportsNovember 14, 2024 | reuters.comFuture Fund LLC Sells 25,199 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Future Fund LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 69.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 11,096 shares of the biopharmaceutical company's stock after selling 25,199 shares durinNovember 13, 2024 | marketbeat.comPrincipal Financial Group Inc. Has $25.65 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Principal Financial Group Inc. lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 25.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 448,087 shares of the biopharmacNovember 13, 2024 | marketbeat.comJanney Montgomery Scott LLC Purchases 9,995 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Janney Montgomery Scott LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 38.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,020 shares of the biopharmaceutiNovember 13, 2024 | marketbeat.comArtisan Partners Limited Partnership Adjusts Stake in Halozyme Therapeutics IncNovember 12, 2024 | gurufocus.comWCM Investment Management LLC Decreases Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)WCM Investment Management LLC cut its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 3.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 300,045 shares of the biopharmacNovember 12, 2024 | marketbeat.comAssetmark Inc. Has $5.33 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Assetmark Inc. boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 9.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 93,159 shares of the biopharmaceutical company's stock after buying an additional 8,38November 12, 2024 | marketbeat.comHere's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth TodayNovember 8, 2024 | msn.comFoster & Motley Inc. Makes New $609,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Foster & Motley Inc. acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 10,650 shares of the biopharmaceutical company's stock, valued at aNovember 8, 2024 | marketbeat.comKornitzer Capital Management Inc. KS Sells 80,870 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Kornitzer Capital Management Inc. KS reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 15.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 441,864 shares of the biopharmaceutical company's stock after selling 80,870November 7, 2024 | marketbeat.comHanseatic Management Services Inc. Makes New $581,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Hanseatic Management Services Inc. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,153 shares of the biopharmaceuNovember 7, 2024 | marketbeat.comBicycle Therapeutics ADR Reaches 80-Plus Relative Strength Rating BenchmarkNovember 5, 2024 | msn.comHalozyme (HALO) Receives a Hold from Piper SandlerNovember 5, 2024 | markets.businessinsider.comHalozyme price target raised to $52 from $51 at Piper SandlerNovember 5, 2024 | markets.businessinsider.comHalozyme: Looking For More Growth Following Record Q3 EarningsNovember 5, 2024 | seekingalpha.comCatalyst Capital Advisors LLC Acquires Shares of 33,965 Halozyme Therapeutics, Inc. (NASDAQ:HALO)Catalyst Capital Advisors LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,965 shares of the biophNovember 5, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, Piper Sandler Analyst SaysPiper Sandler boosted their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a "neutral" rating in a research report on Monday.November 4, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Position Reduced by Assenagon Asset Management S.A.Assenagon Asset Management S.A. lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 91.2% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 3,880 shares of the biopharmaceutical company's stock after selling 40,070 shares during the perNovember 4, 2024 | marketbeat.comResults: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesNovember 3, 2024 | finance.yahoo.com12,729 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by VELA Investment Management LLCVELA Investment Management LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 12,729 shares of the biopharmaceutical compNovember 2, 2024 | marketbeat.comHalozyme’s Robust Q3 2024 Performance and Promising Growth Outlook Justify Buy RatingNovember 2, 2024 | markets.businessinsider.comHalozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...November 2, 2024 | finance.yahoo.comHalozyme Therapeutics Reports Strong Q3 2024 ResultsNovember 2, 2024 | markets.businessinsider.comHalozyme price target raised to $68 from $65 at H.C. WainwrightNovember 2, 2024 | markets.businessinsider.comHalozyme Therapeutics (NASDAQ:HALO) Shares Gap Up on Analyst UpgradeHalozyme Therapeutics (NASDAQ:HALO) Shares Gap Up Following Analyst UpgradeNovember 1, 2024 | marketbeat.comJMP Securities Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $73.00JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research report on Friday.November 1, 2024 | marketbeat.comStephens Investment Management Group LLC Has $77.83 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Stephens Investment Management Group LLC decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,359,730 shares of the biopharmaceutical company's stock after selling 62,17November 1, 2024 | marketbeat.com Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] HALO Media Mentions By Week HALO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼0.670.46▲Average Medical News Sentiment HALO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼258▲HALO Articles Average Week Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IOVA News Today TWST News Today RLAY News Today ADPT News Today ALLO News Today KOD News Today FATE News Today BIIB News Today UTHR News Today INCY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
